Fiche du document
2012
- doi: 10.1007/s00018-012-0989-2
- issn: 1420-682X
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1007/s00018-012-0989-2
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/22527721
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1420-9071
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_A93C669EA17D3
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
TherapyCiter ce document
K. Ludigs et al., « Type I IFN-mediated regulation of IL-1 production in inflammatory disorders. », Serveur académique Lausannois, ID : 10.1007/s00018-012-0989-2
Métriques
Partage / Export
Résumé
Although contributing to inflammatory responses and to the development of certain autoimmune pathologies, type I interferons (IFNs) are used for the treatment of viral, malignant, and even inflammatory diseases. Interleukin-1 (IL-1) is a strongly pyrogenic cytokine and its importance in the development of several inflammatory diseases is clearly established. While the therapeutic use of IL-1 blocking agents is particularly successful in the treatment of innate-driven inflammatory disorders, IFN treatment has mostly been appreciated in the management of multiple sclerosis. Interestingly, type I IFNs exert multifaceted immunomodulatory effects, including the reduction of IL-1 production, an outcome that could contribute to its efficacy in the treatment of inflammatory diseases. In this review, we summarize the current knowledge on IL-1 and IFN effects in different inflammatory disorders, the influence of IFNs on IL-1 production, and discuss possible therapeutic avenues based on these observations.